Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cilostazol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genovate Plans NDA Submission for PMR to FDA in Second Half of 2025
Details : PMR, a novel extended-release formulation of cilostazol is being evaluated in the early-stage clinical trial studies for the treatment of Intermittent Claudication.
Product Name : PMR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Cilostazol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable